A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. (BOREALIS-1)
A Phase 1 First-in-Human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-4001 Monotherapy and in Combination in Patients With Advanced Solid Tumors
Sponsor: Erasca, Inc.
Listed as NCT07021898, this PHASE1 trial focuses on Metastatic Solid Tumors and remains actively recruiting participants. Sponsored by Erasca, Inc., it has been updated 5 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Oct 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Erasca, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .